KIP Infrastructure
2.12.0 - ci-build
KIP Infrastructure, published by Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S. This guide is not an authorized publication; it is the continuous build for version 2.12.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/KIP-infrastructure/implementation-guide/ and changes regularly. See the Directory of published versions
| Official URL: https://kip.rkkp.dk/fhir/ValueSet/Immunoterapi | Version: 2.12.0 | |||
| Active as of 2022-07-18 | Computable Name: Immunoterapi | |||
Immunoterapi
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
This value set includes codes based on the following rules:
https://kip.rkkp.dk/fhir/CodeSystem/GenericValues| Code | Display | Definition |
| none | Ingen immunoterapi | None - used to choose none of the available values |
https://kip.rkkp.dk/fhir/CodeSystem/ATC
| Code | Display | Definition |
| L01FA01 | Rituximab | L01FA01 - rituximab |
| L01FA03 | Obinutuzumab | L01FA03 - obinutuzumab |
| L01FA02 | Ofatumumab | L01FA02 - ofatumumab |
| L04AA | MabCampath | L04AA - Selective immunosuppressants |
| L01FX05 | Brentuximab vedotin (Adcetris) | L01FX05 - brentuximab vedotin |
| L01FX14 | Polatuzumab incl evt. Rituximab | L01FX14 - polatuzumab vedotin |
| L01FF | PD(L)1 hæmmere | L01FF - PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
https://kip.rkkp.dk/fhir/CodeSystem/TreatmentUnspecified
| Code | Display | Definition |
| glofitamab | Glofitamabel Epcoritamab Incl evt. Rituximab | Glofitamab |
Expansion performed internally based on:
This value set contains 9 concepts
| Code | System | Display | Definition |
| none | https://kip.rkkp.dk/fhir/CodeSystem/GenericValues | Ingen immunoterapi | None - used to choose none of the available values |
| L01FA01 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Rituximab | L01FA01 - rituximab |
| L01FA03 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Obinutuzumab | L01FA03 - obinutuzumab |
| L01FA02 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Ofatumumab | L01FA02 - ofatumumab |
| L04AA | https://kip.rkkp.dk/fhir/CodeSystem/ATC | MabCampath | L04AA - Selective immunosuppressants |
| L01FX05 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Brentuximab vedotin (Adcetris) | L01FX05 - brentuximab vedotin |
| L01FX14 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Polatuzumab incl evt. Rituximab | L01FX14 - polatuzumab vedotin |
| L01FF | https://kip.rkkp.dk/fhir/CodeSystem/ATC | PD(L)1 hæmmere | L01FF - PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| glofitamab | https://kip.rkkp.dk/fhir/CodeSystem/TreatmentUnspecified | Glofitamabel Epcoritamab Incl evt. Rituximab | Glofitamab |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |